Company Information

    Ablacon was founded on January 2015. The company is based in Wheat Ridge, CO, USA . The number of employees in Ablacon is less than 50. Ablacon is a wheat ridge, colorado-based provider of ai-guided atrial fibrillation therapies.

    Here is how Ablacon describes itself: "Electrographic Flow is a novel technique to create full temporospatial visualizations of organized action potential flow within Atrial Fibrillation."
      If you are the founder or part of the founding team, please tell the world your story


          Funding & investors

          Ablacon has received 4 rounds of venture funding. The total funding amount is around $63.5M. Last venture funding round was $30M, announced on January, 2021.

            Similar Companies [beta]

              Venture Categories

                Active Venture Investors




                  Venture Competitors

                    News

                        Ablacon - Blog

                          • First-in-man demonstration of 18-month spatiotemporal stability of active atrial fibrillation source detected by Electrographic Flow mapping in persistent atrial fibrillation

                          • The aim of this first-in-man Case report is to demonstrate the spatiotemporal stability and long-term reproducibility of a putative AF source in a patient suffering from long-standing persistent AF associated with hypertrophic cardiomyopathy, by comparing EGF maps recorded 18 months apart.The post First-in-man demonstration of 18-month spatiotemporal stability of active atrial fibrillation source detected by Electrographic Flow mapping in persistent atrial fibrillation appeared first on Ablacon.
                          • Functional Electrographic Flow Patterns in Patients with Persistent Atrial Fibrillation Predict Outcome of Catheter Ablation

                          • Electrographic flow (EGF) mapping is a method to detect action potential sources within the atria. In a double-blinded retrospective study we evaluated whether sources detected by EGF are related to procedural outcome.The post Functional Electrographic Flow Patterns in Patients with Persistent Atrial Fibrillation Predict Outcome of Catheter Ablation appeared first on Ablacon.
                          • $30 Million Series B Financing and Expansion of Scientific Advisory Board

                          • Ablacon, Inc., an Ajax Health-backed company, announced the close of a $30 million Series B financing, with Zeus Health joining as new lead investor.  Ablacon also announced the addition of Dr. David Haines, Professor of Cardiovascular Medicine at Oakland University William Beaumont School of Medicine and Director of the Heart Rhythm Center at Beaumont Health, Royal Oak, MI, to the company’s scientific advisory board (SAB).…The post $30 Million Series B Financing and Expansion of Scientific Advisory Board appeared first on Ablacon.
                          • Ablacon Announces Release of New and Improved Ablamap Technology Under Existing CE Mark

                          • MENLO PARK, Calif., Sept. 10, 2019 /PRNewswire/ — Ablacon, Inc. (www.ablacon.com), an Ajax Health-funded company, announced today the release of an updated version of its Ablamap technology under the company’s existing CE Mark.  The new update includes an enhanced physician experience and user interface, along with significantly faster processing times leading to improved procedural efficiency. …The post Ablacon Announces Release of New and Improved Ablamap Technology Under Existing CE Mark appeared first on Ablacon.
                          • Ablacon Announces Closing of a $10 Million Venture Debt Facility and $2 Million Equity Investment from Western Technology Investment; Josef Koblish and Melissa Kong to Join the Company

                          • MENLO PARK, Calif., July 23, 2019 /PRNewswire/ — Ablacon Inc. announced today that it has entered into a $10 millionventure debt facility with Western Technology Investment (WTI). The debt is accompanied by a $2 million equity investment in the Company. This financing will help fund Ablacon’s first multicenter randomized clinical trial for Ablamap, an advanced mapping system for patients with atrial fibrillation.…The post Ablacon Announces Closing of a $10 Million Venture Debt Facility and $2 Million Equity Investment from Western Technology Investment; Josef Koblish and Melissa Kong to Join the Company appeared first on Ablacon.
                          • Forbes lists Ablacon “25 Top Machine Learning Startups To Watch In 2019”

                          • From powering personalized career sites that recommend open positions that are ideal for a given candidate based on their capabilities as eightfold.ai does today, to scaling the complexity and volume of machine learning algorithms, so they’re more accessible as DataRobot does, machine learning startups are taking on many of business’ most significant challenges.…The post Forbes lists Ablacon “25 Top Machine Learning Startups To Watch In 2019” appeared first on Ablacon.

                          Share:     facebook    twitter    linkedin    reddit    email

                            Ventures Media is one of the largest startup and venture capital communities for startup and venture capital funding information and analysis.

                            Leave a Reply

                            Your email address will not be published. Required fields are marked *